# FDA Finalizes Section 564 Emergency IVD Validation Guidance

The U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) has finalized [_Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency_](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/validation-certain-in-vitro-diagnostic-devices-emerging-pathogens-during-section-564-declared-emergency) (Document GUI00007020). Published with a companion [Federal Register Notice of Availability (91 FR 72541)](https://www.govinfo.gov/content/pkg/FR-2026-11-10/pdf/2026-22883.pdf) on **10 November 2026**, the [final guidance PDF](https://www.fda.gov/media/184852/download) finalizes the **7 January 2025** draft (90 FR 1168) and links to a companion [General IVD EUA/Pre-EUA Template](https://www.fda.gov/media/184828/download).

The guidance contains **nonbinding recommendations** for pre-EUA submissions, Emergency Use Authorization (EUA) requests under Section 564 of the FD&C Act, and tests offered under an applicable enforcement-discretion policy. Sponsors can submit a pre-EUA before a declaration. An EUA request requires a current applicable declaration.

## Scope, Legal Authority, and Key Finalization Changes

The guidance applies to diagnostic IVDs defined under 21 CFR 809.3—including tests for screening asymptomatic individuals and home-use tests—that detect emerging pathogens to aid diagnosis of serious or life-threatening infectious diseases or conditions covered by an applicable Section 564 declaration. It also addresses home specimen collection kits and certain software used with diagnostic tests. Serology, antibody and other adaptive immune response tests are outside its scope (Section III, pages 2–3).

FDA stresses that EUAs rely on the statutory **"may be effective"** standard (FD&C Act section 564(c)(2)(A)), which differs from the clearance and approval effectiveness standards under Sections 513 and 515 and 21 CFR 860.7 (Section V, page 4). Compared with the January 2025 draft, the Notice (91 FR 72542) and final guidance text identify these changes:

-   **Draft "PCCPs" renamed to "Change Protocols":** Section V (_Change Protocols_, pages 12–13, footnote 32) explains that Predetermined Change Control Plans (PCCPs) apply only to marketing submissions, not EUAs. For EUAs, a manufacturer can propose a protocol for future changes within the device’s intended use, such as adding an instrument or collection device. A change carried out under a protocol FDA reviewed and included in the initial EUA is considered covered by that authorization. FDA generally specifies implementation requirements in a condition of authorization.
-   **Consolidated recommendations and outbreak-stage flexibility:** According to the Notice of Availability (91 FR 72542), FDA revised the draft in response to comments to provide consolidated, streamlined validation recommendations across diagnostic test types, emphasize flexibility across different outbreak stages, and clarify its focus on the most important and least burdensome information to collect or submit during a Section 564 declared emergency.
-   **Distinct from FDA's 2025 emergency policy guidance:** This scientific validation guide complements, rather than duplicates, CDRH's earlier January 2025 general Section 564 IVD policy framework summarized in our coverage of [FDA's emergency-use IVD policy guidance](https://www.pureglobal.com/news/fda-finalizes-guidance-on-emergency-use-of-ivds-during-public-health-crises-2025).

## Clinical and Analytical Validation Benchmarks

| Study Domain | FDA Non-Binding Recommendation (GUI00007020) | Locator & Key Qualification |
| :-- | :-- | :-- |
| **Clinical specimen selection** | FDA prefers natural specimens from a prospective study. Early in an outbreak, archived specimens may be a reasonable alternative. If neither is available, FDA may accept contrived samples. Synthetic material may be acceptable when pathogen stocks are unavailable. FDA would likely require a follow-up study with natural specimens once feasible if it authorizes a test on contrived validation data. | Section V, _Clinical Performance Evaluation_ & (1) (pp. 5–6) |
| **Clinical sample size & CIs** | For an established high-sensitivity viral nucleic acid test when clinical specimens and comparators are generally available, FDA gives **at least 30 positive and 30 negative** specimens as a typical example. FDA generally recommends reporting positive and negative percent agreement (PPA and NPA) with a highly sensitive comparator and **95% Wilson Score confidence intervals**. | Section V, _Clinical Performance Evaluation_ & (3) (pp. 5–7); Footnote 11 describes a withdrawn COVID-19 EUA request. Cumulative PPA was 71% after the first 12 positive samples and 12 additional samples were evaluated. |
| **Human subjects / IRB waiver** | An IRB may waive or alter informed consent for some minimal-risk investigations that meet 21 CFR 50.22. FDA separately references its consent policy for certain leftover specimens that cannot be individually identified. | Section V, _Clinical Performance Evaluation (4)_ (p. 8) |
| **Confirmatory LoD** | Preliminary 2–3-fold dilution range-finding (3 replicates/level), followed by **at least 20 individual replicates** at the preliminary LoD. The final LoD is the lowest concentration at which at least 95% are positive (for example, 19 of 20). | Section V, _Analytical Validation Testing (1)_ (pp. 8–9). FDA advises against simulated matrix or recombinant antigen for LoD studies. |
| **Inclusivity & variants** | _In silico_ alignment (100% nucleotide sequence identity for molecular tests, or risk assessment for mismatches with a significant number of published sequences), with wet testing for circulating variants when available. FDA recommends **monthly inclusivity evaluation** for clinically significant mutations and a risk analysis for a **greater than 3-fold reduction** in analytical sensitivity. FDA also recommends checking whether the aggregate impact brings clinical performance below its recommendations. | Section V, _Analytical Validation Testing (2)_ (p. 9) |
| **Specimen stability** | Where applicable CDC specifications cover the proposed conditions, FDA says additional data are likely unnecessary. Otherwise, evaluate the proposed storage and transport conditions using live or inactivated pathogen spiked into negative clinical matrix around the LoD plus **at least 10 negative specimens**. | Section V, _Analytical Validation Testing (3)_ (p. 10) |

## Home-Use, Comprehension, and Point-of-Care (POC) Recommendations

Section V (_Analytical Validation Testing (5)_, pages 11–12) and Section VI (pages 13–15) set usability, labeling, and operational expectations when manufacturers pursue home-collection kits, over-the-counter home tests, or POC settings intended for CLIA-waived use.

-   **Quick Reference Instructions (QRI), comprehension, and flex studies:** FDA recommends limiting lay-user QRIs to **1 to 2 pages**, written at **no higher than a 7th-grade reading level**, and supported with pictures and diagrams (Section VI, pages 13–15), alongside usability, user comprehension, and hazard-based flex studies under Section V (_Analytical Validation Testing (5)_, pages 11–12).
-   **Near-cutoff POC evaluation:** For POC tests intended for CLIA-waived settings, FDA recommends testing across **1–2 U.S. sites** with **4–6 operators without laboratory training** representative of intended users (e.g., non-laboratorian healthcare professionals or untrained non-healthcare users in non-traditional settings), with a separate near-LoD evaluation using **10 contrived specimens near the LoD** (for example, within **3-fold**) and **10 negative specimens** per site. Each operator should test **at least 3 positives and 3 negatives**, targeting **≥ 95% positive and negative agreement** (or re-evaluating the LoD).

## Practical Implications for IVD Developers

**Pure Global analysis:** Developers can use the guidance to prepare a validation plan and identify decisions to discuss with FDA in a pre-EUA submission.

1.  **Plan how to obtain natural clinical specimens.** Decide what evidence could be collected early and how a later clinical study would follow once natural patient specimens become available. For an infectious disease test, identify a sensitive comparator with performance data for the intended specimen type.
2.  **Decide which foreseeable changes merit an EUA change protocol.** When preparing an EUA request using the companion [General IVD EUA/Pre-EUA Template](https://www.fda.gov/media/184828/download), consider documenting the proposed changes, validation, acceptance criteria and labeling updates.
3.  **Assign responsibility for variant monitoring.** Identify who will review emerging mutations each month, assess performance concerns and escalate a greater than 3-fold sensitivity loss for risk analysis.

[Canonical page](https://www.pureglobal.com/news/fda-final-guidance-ivd-validation-emerging-pathogens-section-564)
